The Servier case: The game isn’t over yet -
The European Court of Justice recently issued seven judgments in the landmark "Servier" case, confirming the anticompetitive nature of "pay-for-delay" agreements between...more
Le 27 juin 2024, le laboratoire pharmaceutique Servier – qui, entre 2005 et 2007, avait conclu plusieurs accords transactionnels en matière de brevets impliquant des paiements inversés avec des génériqueurs (Niche/Unichem,...more
The ECJ confirms its intolerance against conduct that is viewed as originator companies buying off competition from generic companies about to enter the market and thereby unduly prolonging their monopoly. Such conduct, which...more
On 9 September 2020, the French Competition Authority (“FCA”) issued an infringement decision sanctioning Novartis and Roche with record fines for the pharmaceutical sector in France, totaling 444 million euros, for having...more
1/28/2021
/ Biotechnology ,
Competition ,
Enforcement Actions ,
France ,
French Competition Authority ,
Genentech ,
Infringement ,
Life Sciences ,
Novartis ,
Off-Label Use ,
Pharmaceutical Industry
On 12 December 2018, the General Court (“Court”) partially annulled the European Commission’s decision of 9 July 2014 in the Servier case and consequently reduced Servier’s fine by more than 30%, from €330.99 million to...more
12/21/2018
/ Abuse of Dominance ,
Annulment ,
Anti-Competitive ,
Antitrust Violations ,
EU ,
European Commission ,
European Patent Office ,
Fee Reductions ,
General Court of the European Union (GCEU) ,
Generic Drugs ,
IP License ,
Patent Validity ,
Patents ,
Pay-For-Delay ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Reverse Payment Settlement Agreements ,
Settlement Agreements ,
Treaty on the Functioning of the European Union (TFEU)
The UK Competition and Markets Authority (“CMA”) recently published its infringement decision of 7 December 2016 that imposed a fine on Pfizer and Flynn Pharma (“Flynn”) for abusing their respective dominant positions by...more
9/22/2017
/ Abuse of Dominance ,
Antitrust Investigations ,
Appeals ,
Cancer ,
Drug Pricing ,
Excessive Pricing ,
Fines ,
Infringement ,
Medicines and Healthcare Products Regulatory Agency (MHRA) ,
National Health Service Corp (NHSC) ,
Pfizer ,
Pharmaceutical Industry ,
Prescription Drugs ,
UK ,
UK Competition and Markets Authority (CMA)